A Study of the Novel Drug Dimebon in Patients With Huntington's Disease
NCT00497159
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Clinical features of HD and a confirmatory family history of HD, and/or genetically confirmed HD;
- Able to take medication (capsules) by mouth.
- Clinical evidence of unstable medical illness;
- Females who are pregnant or lactating or who intend to become pregnant during the
study period.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Paris Cedex 13,
- Birmingham, Alabama
- Birmingham, Alabama
- Birmingham, Alabama
- Phoenix, Arizona
- Scottsdale, Arizona
- Irvine, California
- Los Angeles, California
- Los Angeles, California
- Los Angeles, California
- Englewood, Colorado
- Gainesville, Florida
- Indianapolis, Indiana
- Charlestown, Massachusetts
- Saint Louis, Missouri
- Albany, New York
- Winston-Salem, North Carolina
- Cleveland, Ohio
- Cleveland, Ohio
- Columbus, Ohio
- Columbus, Ohio
- Columbus, Ohio
- Houston, Texas
- Vancouver, British Columbia
- Toronto, Ontario
- Montreal, Quebec
- Montreal, Quebec
- Munchen, Bavaria
- Aachen,
- Berlin,
- Bochum,
- Erlangen,
- Freiburg,
- Lubeck,
- Marburg,
- Münster,
- Taufkirchen,
- Ulm,
- Wuerzburg,
- Gdansk,
- Krakow,
- Poznan,
- Warszawa,
- Aberdeen, Aberdeenshire
- Southampton, Hampshire
- Oxford, Oxfordshire
- Sheffield, South Yorkshire
- Birmingham, West Midlands
- Cambridge,
- Cardiff,
- Glasgow,
- London,
- London,
- London,
- Manchester,
- Manchester,
- Newcastle Upon Tyne,
- Newcastle Upon Tyne,
- Birmingham, Alabama
- Birmingham, Alabama
- Scottsdale, Arizona
- Irvine, California
- Los Angeles, California
- Los Angeles, California
- Los Angeles, California
- Englewood, Colorado
- Gainesville, Florida
- Indianapolis, Indiana
- Saint Louis, Missouri
- Albany, New York
- Winston-Salem, North Carolina
- Columbus, Ohio
- Columbus, Ohio
- Columbus, Ohio
- Houston, Texas
- Vancouver, British Columbia
- Toronto, Ontario
- Montreal, Quebec
- Montreal, Quebec
- Aachen,
- Berlin,
- Bochum,
- Erlangen,
- Lübeck,
- Marburg,
- Munchen,
- Münster,
- Taufkirchen,
- Ulm,
- Wuerzburg,
- Gdansk,
- Krakow,
- Poznan,
- Warszawa,
- Oxford Road, Manchester
- Gosforth, Newcastle UPON TYNE
- Birmingham, WEST Midlands
- Aberdeen,
- Cardiff,
- Glasgow,
- London,
- London,
- London,
- Manchester,
- Newcastle upon Tyne,
- Oxford,
- Sheffield,
- Southampton,
- Rochester, New York
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | A Study of the Novel Drug Dimebon in Patients With Huntington's Disease | |||
Official Title ICMJE | A Multi-Center, Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study of Dimebon in Subjects With Huntington's Disease | |||
Brief Summary | This study will evaluate the safety of 3 months of Dimebon dosing and the efficacy of Dimebon in improving cognitive, motor, and overall function in subjects with Huntington's Disease. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 2 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment | |||
Condition ICMJE | Huntington's Disease | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Kieburtz K, McDermott MP, Voss TS, Corey-Bloom J, Deuel LM, Dorsey ER, Factor S, Geschwind MD, Hodgeman K, Kayson E, Noonberg S, Pourfar M, Rabinowitz K, Ravina B, Sanchez-Ramos J, Seely L, Walker F, Feigin A; Huntington Disease Study Group DIMOND Investigators. A randomized, placebo-controlled trial of latrepirdine in Huntington disease. Arch Neurol. 2010 Feb;67(2):154-60. doi: 10.1001/archneurol.2009.334. Erratum in: Arch Neurol. 2010 Apr;67(4):492. Dimebon in Subjects With Huntington Disease (DIMOND)Investigators of the Huntington Study Group [corrected to Huntington Disease Study Group DIMOND Investigators]. | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 91 | |||
Original Estimated Enrollment ICMJE | 90 | |||
Actual Study Completion Date ICMJE | June 2008 | |||
Actual Primary Completion Date | June 2008 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 29 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00497159 | |||
Other Study ID Numbers ICMJE | DIM05 | |||
Has Data Monitoring Committee | Yes | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Medivation, Inc. | |||
Study Sponsor ICMJE | Medivation, Inc. | |||
Collaborators ICMJE | Huntington Study Group | |||
Investigators ICMJE |
| |||
PRS Account | Medivation, Inc. | |||
Verification Date | May 2015 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |